Cell line development market at high investment in research by pharmaceutical companies to develop new product
A cell line is a long established cell culture that continues to proliferate in fresh media. The development of cell lines is used to test the efficacy and toxicity of drug discovery. It is required for making recombinant proteins such as chemotherapy drugs, bispecific biologics, cell proliferation and enzymatic use of a range of expression methods. Cell lines save time, effort, and money by providing high-yielding cells that can be used for in vitro testing, reducing the risk of an investigational drug failure during the phase. clinical trial.
Request trend sample of this report:
To propel the cell line development market, new therapies are being developed. The creation of cell lines has a wide range of applications. Development of cell lines is widely used in the development of immunotherapy for the treatment of cancer. According to a 2018 World Health Organization fact sheet, cancer is the second leading cause of death worldwide, with 9.6 million deaths in 2018. Due to its specificity and effectiveness, cancer pharmaceutical and biotechnology companies are focused on creating new treatments such as immunotherapy. By providing high production of monoclonal antibodies, cell line development helps to speed up the drug discovery process and modify screening assays, which is expected to drive the global cell line development market forward.
The global cell line development market is expected to increase owing to increasing technical developments in the field. The Lonza group introduced the culture of multiplex cell lines using the GS Xceed gene expression system in November 2017, which helps to assess many drug candidates at an early stage of development, saving four to six months that would otherwise be required. in traditional development.
Due to the large spending by pharmaceutical companies for the creation of a unique study conducted and the increase in patenting of key products, which would stimulate the development of biosimilar drugs, North America is expected to maintain its dominant position in the market. global development of cell lines. Due to the high number of off-patent drugs and medical service reforms favoring the advancement of generic drugs, generic drug sales in the United States totaled US $ 70 billion in 2015, accounting for about 25% of the global market, according to a 2016 report from the International Trade Administration of the Department of Commerce (United States). Biologics make up more than a third of all new drugs in clinical trials or pending FDA clearance, according to the same research. According to Pharmaceutical Research and Manufacturers of America, companies in the United States such as Novartis AG, Merck and Company and F. Hoffmann-La Roche AG have invested a total of US $ 75 billion in R&D activities.
Cell line development companies are collaborating with drug discovery companies to accelerate the growth of the global cell line development market.
Request a PDF Brochure Report –
The major companies contributing to the global cell line development market are Thermo Fisher Scientific, Inc., Selexis SA, American Type Culture Collection, Wuxi App Tec, Inc., Sigma-Aldrich Corporation, Goodwin Biotechnology Inc., Lonza Group AG, Cleancells , Sartorious AG, Corning, Inc., European Collection of Cell Cultures, GE Healthcare and PX’Therapeutics SA.
Turgut Pharmaceuticals and Selexis SA announced a third advertising license agreement in December 2017 that would give Turgut direct exposure to Selexis’ SUREtechnology platform and SURE CHO-M cell line for the advancement of biosimilars for the treatment of two rare diseases: paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies had previously agreed (in July 2016) to use SURE CHO-M cell lines to create biosimilar drugs to treat inflammatory disorders and malignant tumors.
CBMG and GE Healthcare announced a cooperation in April 2017 to produce stem cells for the creation of cell lines.
PX’Therapeutics established a cooperation with the biotechnology company Advaxis in January 2018 for the integration of Advaxis immunotherapy systems.
Denali Therapeutics and Lonza partnered in February 2018 to research and manufacture biological therapeutics using Lonza’s GS Xceed cell line development technology.
Manufacturing companies are focusing on diversifying their business portfolios in order to strengthen their brand reputation and expand their customer base. Lonza and Sanofi entered into a strategic collaboration in February 2017 with the aim of establishing mammalian cell facilities in Switzerland to generate monoclonal antibodies.
Reasons to buy this report
Current and future prospects of the global cell line development market in developed and emerging markets
The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
Regions / countries expected to experience the fastest growth rates during the forecast period
The latest developments, market shares and strategies used by major market players
Buy this Complete an activity report with a discount of US $ 2000 @
Market taxonomy of cell line development
Based on the type of product:
- Reagents and media
Based on the source:
Based on the cell line:
- Continuous cell line
- Primary cell line
Based on demand:
- Drug discovery
- Toxicity tests
- Fabric creation
Based on the end user:
- Pharmaceutical companies
- Research institution and university
Based on the Region:
- North America
- Latin America
- Asia Pacific
- Middle East
The content of the study topics includes a total of 15 chapters:
Chapter 1, to describe Cell Line Development product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, to profile the leading manufacturers of Cell Line Development, with price, sales, revenue and global market share of Cell Line Development in 2018 and 2020.
Chapter 3, The competitive situation of Cell lines development market trends, sales, revenue and global market share of major manufacturers are analyzed forcefully by landscape contrast.
Chapter 4, Cell Line Development breakdown data is presented regionally, to show sales, revenue and growth by regions, from 2016 to 2020.
Chapter 5, 6, 7, 8 and 9, to break down country-level sales data, with sales, revenue and market share for key countries in the world, from 2016 to 2020.
Chapter 10 and 11, segment sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2020.
Chapter 12, Cell lines development market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Cell Line Development sales channel, distributors, customers, research results and conclusion, appendix and data source.
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients from all walks of life, from Fortune 500 companies to nonprofits and startups looking to gain a foothold in the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837